- Abelacimab reduced major bleeding that usually required hospitalization and bleeding that required medical attention but not hospitalization by 67% at a dose of 150 mg and 77% at a dose of 90 mg, compared to rivaroxaban.
- At a dose of 150 mg, abelacimab reduced major bleeding by 74% compared to rivaroxaban; and at a dose of 90 mg, it reduced major bleeding by 81%.
- Both doses of abelacimab reduced gastrointestinal bleeding by 93% compared to rivaroxaban.
- Abelacimab was well tolerated with similar rates of adverse events compared with rivaroxaban.
- Abelacimab is an injectable, monoclonal antibody, categorized as a factor XI inhibitor, that has the potential to prevent the clots that cause strokes and heart attacks while preserving the body’s natural ability to repair blood vessels during an injury. This could lower the risk of bleeding for people who take it.
- The study enrolled 1,287 adults across 95 global study sites including the U.S. and Canada, Europe and Asia between March and December 2021 with median follow-up of 1.8 years.
- Participants were 55-years-old and older (44% women) with a history of AFib and who were taking anticoagulants.
- Participants were at moderate to high risk of stroke as determined by history of congestive heart failure, high blood pressure, their age, Type 2 diabetes and stroke and vascular disease—which is known as the CHA2DS2-VASc score.
- In a 2021 study, abelacimab was shown to effectively prevent blood clots among people who had knee replacement surgery.
Source: Read Full Article